OncoMyx is developing potentially best-in-class (multi-armed, IV/systemically-delivered, precision medicine) oncolytic immunotherapies based upon the myxoma virus (MYXV) platform, and the company has demonstrated mechanism of action and combinatorial efficacy (tumor growth inhibition) when dosed IV with various checkpoint inhibitors in multiple animal models. The company has the industry’s most experienced oncolytic virus (OV) development team and an experienced SAB, and CEO Steve Potts was previously an executive at Ignyta (acquired by Roche for $1.7B). OncoMyx raised a $25M series A in June 2019 to advance its lead preclinical program to IND. And on the heels of presenting its preclinical data at SITC and announcing the appointment of Mirati CEO Chuck Baum as its new Chairperson, OncoMyx Therapeutics is beginning to fundraise for a $50M series B and transition into a clinical-stage organization.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
OM101 for solid tumors
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):